<p>Recursion Pharmaceuticals, Inc.（纳斯达克代码：RXRX - 获取免费报告）周一下跌了 6.9%。该公司的股价最低跌至 6.01 美元，最后交易价为 6.14 美元。在午盘交易中，约有 8,113,213 股成交，较日均成交量 25,409,162 股下降了 68%。该股票此前收盘价为 6.59 美元。</p>
<h2>分析师评级变动</h2>
<ul>
<li>突然上升：Recursion Pharmaceuticals 是 NVIDIA 的 AI 宠儿吗？</li>
</ul>
<p>RXRX 已成为多份研究分析师报告的主题。KeyCorp 在 1 月 8 日的报告中将 Recursion Pharmaceuticals 的目标价从 12.00 美元下调至 10.00 美元，并对该股票给予 “增持” 评级。Needham &amp; Company LLC 在 2 月 6 日的研究报告中重申了 “买入” 评级，并将 Recursion Pharmaceuticals 的目标价设定为 11.00 美元。Cowen 在 2 月 28 日的报告中重申了对 Recursion Pharmaceuticals 的 “持有” 评级。最后，Leerink Partners 在 2 月 28 日的研究报告中将 Recursion Pharmaceuticals 的目标价从 7.00 美元下调至 6.00 美元，并对该公司设定了 “市场表现” 评级。三位股票研究分析师对该股票给予了持有评级，两位给予了买入评级。根据 MarketBeat 的数据，Recursion Pharmaceuticals 的平均评级为 “持有”，平均目标价为 8.25 美元。</p>
<p><strong>查看我们关于 RXRX 的最新报告</strong></p>
<h2>Recursion Pharmaceuticals 价格表现</h2>
<ul>
<li>生物科技处于边缘：两只具有巨大潜力的股票</li>
</ul>
<p>该股票的 50 日移动平均线为 7.64 美元，200 日移动平均线为 7.07 美元。该股票的市值为 24 亿美元，市盈率为-4.01，贝塔值为 0.85。该公司的债务与股本比率为 0.04，流动比率为 4.35，速动比率为 4.35。</p>
<p>Recursion Pharmaceuticals（纳斯达克代码：RXRX - 获取免费报告）最后一次公布季度财报是在 2 月 28 日。该公司报告每股收益为（0.53 美元），低于分析师一致预期的（0.36 美元），差额为（0.17 美元）。该公司在本季度的收入为 460 万美元，而分析师预期为 1904 万美元。Recursion Pharmaceuticals 的净利润率为-579.52%，股本回报率为-76.56%。与去年同期相比，Recursion Pharmaceuticals 本季度的收入下降了 57.8%。在去年同期，该公司每股收益为（0.42 美元）。作为一个整体，卖方分析师预测 Recursion Pharmaceuticals, Inc.在当前财年将发布每股收益-1.57 美元。</p>
<h2>机构投资者对 Recursion Pharmaceuticals 的看法</h2>
<ul>
<li>AI 制药：通往 AI 驱动药物投资的两条路径</li>
</ul>
<p>几家对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Decker Retirement Planning Inc.在第四季度购买了价值约 26,000 美元的 Recursion Pharmaceuticals 新头寸。Private Trust Co. NA 在第四季度获得了价值 27,000 美元的 Recursion Pharmaceuticals 新股份。GAMMA Investing LLC 在第四季度将其在 Recursion Pharmaceuticals 的持仓提高了 1,979.2%。GAMMA Investing LLC 现在拥有 5,198 股该公司股票，价值 35,000 美元，此前在上个季度增持了 4,948 股。Farther Finance Advisors LLC 在第三季度将其在 Recursion Pharmaceuticals 的持仓提高了 176.9%。Farther Finance Advisors LLC 现在拥有 6,404 股该公司股票，价值 42,000 美元，此前在上个季度增持了 4,091 股。最后，KBC Group NV 在第三季度将其在 Recursion Pharmaceuticals 的持仓提高了 79.9%。KBC Group NV 现在拥有 7,602 股该公司股票，价值 50,000 美元，此前在上个季度增持了 3,377 股。机构投资者和对冲基金持有该公司 89.06% 的股份。</p>
<h2>Recursion Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Recursion Pharmaceuticals, Inc.是一家临床阶段的生物技术公司，通过整合生物学、化学、自动化、数据科学和工程等技术创新来解码生物学，以实现药物发现的工业化。该公司开发的 REC-994 正在进行二期临床试验，以治疗脑血管畸形；REC-2282 正在进行二期/三期临床试验，以治疗神经纤维瘤病 2 型；REC-4881 正在进行一期 b/二期临床试验，以治疗家族性腺瘤性息肉病；REC-3964 正在进行一期临床试验，以治疗艰难梭状芽孢杆菌感染；REC-4881 正在进行二期临床试验，以治疗 AXIN1 或 APC 突变癌症。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Recursion Pharmaceuticals 更好</li>
<li>国会股票交易跟踪</li>
<li>如何在通货膨胀上升时保护您的投资组合</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>3 只在 2025 年逆势而上并蓬勃发展的科技股</li>
<li>英国市场假期是什么？如何投资和交易</li>
<li>尽管面临挑战，诺和诺德计划击败 GLP-1 竞争对手</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Recursion Pharmaceuticals 吗？</h2>
<p>在考虑 Recursion Pharmaceuticals 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Recursion Pharmaceuticals 并不在名单上。</p>
<p>虽然 Recursion Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

RXRX

<p>Recursion Pharmaceuticals（纳斯达克代码：RXRX）股价下跌 6.9%，至 6.14 美元，交易量较平均水平下降 68%。分析师的评级不一，KeyCorp 将其目标价从 12 美元下调至 10 美元，而 Needham 则维持 11 美元的买入评级。该公司报告季度每股亏损 0.53 美元，未能达到预期，营收为 460 万美元，远低于预期。机构投资者持有该公司 89.06% 的股份，并且公司正在进行多项针对不同治疗的临床试验</p>

<p>Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) dropped 6.9% on Monday . The company traded as low as $6.01 and last traded at $6.14. Approximately 8,113,213 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 25,409,162 shares. The stock had previously closed at $6.59.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc.（纳斯达克代码：RXRX - 获取免费报告）周一下跌了 6.9%。该公司的股价最低跌至 6.01 美元，最后交易价为 6.14 美元。在午盘交易中，约有 8,113,213 股成交，较日均成交量 25,409,162 股下降了 68%。该股票此前收盘价为 6.59 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?</li>
</ul>
<div class="lb-trans"><ul>
<li>突然上升：Recursion Pharmaceuticals 是 NVIDIA 的 AI 宠儿吗？</li>
</ul>
</div><p>RXRX has been the topic of several research analyst reports. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an &#34;overweight&#34; rating on the stock in a report on Wednesday, January 8th. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Cowen restated a &#34;hold&#34; rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a &#34;market perform&#34; rating for the company in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Recursion Pharmaceuticals has an average rating of &#34;Hold&#34; and an average target price of $8.25.</p>
<div class="lb-trans"><p>RXRX 已成为多份研究分析师报告的主题。KeyCorp 在 1 月 8 日的报告中将 Recursion Pharmaceuticals 的目标价从 12.00 美元下调至 10.00 美元，并对该股票给予 “增持” 评级。Needham &amp; Company LLC 在 2 月 6 日的研究报告中重申了 “买入” 评级，并将 Recursion Pharmaceuticals 的目标价设定为 11.00 美元。Cowen 在 2 月 28 日的报告中重申了对 Recursion Pharmaceuticals 的 “持有” 评级。最后，Leerink Partners 在 2 月 28 日的研究报告中将 Recursion Pharmaceuticals 的目标价从 7.00 美元下调至 6.00 美元，并对该公司设定了 “市场表现” 评级。三位股票研究分析师对该股票给予了持有评级，两位给予了买入评级。根据 MarketBeat 的数据，Recursion Pharmaceuticals 的平均评级为 “持有”，平均目标价为 8.25 美元。</p>
</div><p><strong>Check Out Our Latest Report on RXRX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 RXRX 的最新报告</strong></p>
</div><h2>Recursion Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 价格表现</h2>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技处于边缘：两只具有巨大潜力的股票</li>
</ul>
</div><p>The stock's 50 day moving average is $7.64 and its two-hundred day moving average is $7.07. The stock has a market capitalization of $2.40 billion, a PE ratio of -4.01 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均线为 7.64 美元，200 日移动平均线为 7.07 美元。该股票的市值为 24 亿美元，市盈率为-4.01，贝塔值为 0.85。该公司的债务与股本比率为 0.04，流动比率为 4.35，速动比率为 4.35。</p>
</div><p>Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue for the quarter was down 57.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.42) earnings per share. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals（纳斯达克代码：RXRX - 获取免费报告）最后一次公布季度财报是在 2 月 28 日。该公司报告每股收益为（0.53 美元），低于分析师一致预期的（0.36 美元），差额为（0.17 美元）。该公司在本季度的收入为 460 万美元，而分析师预期为 1904 万美元。Recursion Pharmaceuticals 的净利润率为-579.52%，股本回报率为-76.56%。与去年同期相比，Recursion Pharmaceuticals 本季度的收入下降了 57.8%。在去年同期，该公司每股收益为（0.42 美元）。作为一个整体，卖方分析师预测 Recursion Pharmaceuticals, Inc.在当前财年将发布每股收益-1.57 美元。</p>
</div><h2>Institutional Investors Weigh In On Recursion Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Recursion Pharmaceuticals 的看法</h2>
</div><ul>
<li>AI Pharma: 2 Paths to AI-Powered Drug Investment</li>
</ul>
<div class="lb-trans"><ul>
<li>AI 制药：通往 AI 驱动药物投资的两条路径</li>
</ul>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in the business. Decker Retirement Planning Inc. purchased a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $26,000. Private Trust Co. NA acquired a new stake in Recursion Pharmaceuticals during the 4th quarter worth $27,000. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after acquiring an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after acquiring an additional 4,091 shares in the last quarter. Finally, KBC Group NV increased its position in shares of Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after purchasing an additional 3,377 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Decker Retirement Planning Inc.在第四季度购买了价值约 26,000 美元的 Recursion Pharmaceuticals 新头寸。Private Trust Co. NA 在第四季度获得了价值 27,000 美元的 Recursion Pharmaceuticals 新股份。GAMMA Investing LLC 在第四季度将其在 Recursion Pharmaceuticals 的持仓提高了 1,979.2%。GAMMA Investing LLC 现在拥有 5,198 股该公司股票，价值 35,000 美元，此前在上个季度增持了 4,948 股。Farther Finance Advisors LLC 在第三季度将其在 Recursion Pharmaceuticals 的持仓提高了 176.9%。Farther Finance Advisors LLC 现在拥有 6,404 股该公司股票，价值 42,000 美元，此前在上个季度增持了 4,091 股。最后，KBC Group NV 在第三季度将其在 Recursion Pharmaceuticals 的持仓提高了 79.9%。KBC Group NV 现在拥有 7,602 股该公司股票，价值 50,000 美元，此前在上个季度增持了 3,377 股。机构投资者和对冲基金持有该公司 89.06% 的股份。</p>
</div><h2>Recursion Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc.是一家临床阶段的生物技术公司，通过整合生物学、化学、自动化、数据科学和工程等技术创新来解码生物学，以实现药物发现的工业化。该公司开发的 REC-994 正在进行二期临床试验，以治疗脑血管畸形；REC-2282 正在进行二期/三期临床试验，以治疗神经纤维瘤病 2 型；REC-4881 正在进行一期 b/二期临床试验，以治疗家族性腺瘤性息肉病；REC-3964 正在进行一期临床试验，以治疗艰难梭状芽孢杆菌感染；REC-4881 正在进行二期临床试验，以治疗 AXIN1 或 APC 突变癌症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Recursion Pharmaceuticals</li>
<li>Following Congress Stock Trades</li>
<li>How to Protect Your Portfolio When Inflation Is Rising</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>3 Tech Stocks Defying Sector Weakness and Thriving in 2025</li>
<li>What Are the U.K. Market Holidays? How to Invest and Trade</li>
<li>Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Recursion Pharmaceuticals 更好</li>
<li>国会股票交易跟踪</li>
<li>如何在通货膨胀上升时保护您的投资组合</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>3 只在 2025 年逆势而上并蓬勃发展的科技股</li>
<li>英国市场假期是什么？如何投资和交易</li>
<li>尽管面临挑战，诺和诺德计划击败 GLP-1 竞争对手</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Recursion Pharmaceuticals 吗？</h2>
</div><p>Before you consider Recursion Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Recursion Pharmaceuticals 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Recursion Pharmaceuticals 并不在名单上。</p>
</div><p>While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Recursion Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Recursion Pharmaceuticals (NASDAQ:RXRX) 股价下跌 6.9% - 你应该卖出吗？